Brain Cancer Trial, Recruiting NCT07282470 Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT07282470
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have been diagnosed for the first time with a single meningioma (a type of brain tumour) located on the outer surface of the brain (called the convexity)
  • People who have had surgery where the surgeon was able to remove the entire visible tumour (a level of removal known as Simpson grade 1–3)

For the part of the study looking at past cases only:

  • People whose surgery was performed between 2007 and 2016
  • People for whom preserved tumour tissue samples and medical records are available

Who may not be able to join:

  • People who have a known genetic syndrome
  • People who have a condition where meningiomas are spread widely across the lining of the brain, rather than in a single spot
  • People who received an experimental treatment before their surgery

For the part of the study enrolling new participants only:

  • People who have previously had surgery or other medical treatment for a different or earlier meningioma
  • People with a history of another cancer (for example, breast cancer)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Registry
ClinicalTrials.gov
Start date
25 September 2024
Est. completion
1 March 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Definition of a novel epigenetic signature based on MS-profiling

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov